The U.S. Food and Drug Administration has granted accelerated approval to dostarlimab for patients with a specific type of locally advanced rectal cancer. Clinical trial results showed that many participants required no additional treatment beyond immunotherapy and were able to avoid traditional approaches such as surgery, radiation, and chemotherapy. Experts say the approval represents a significant step forward in precision oncology and personalized cancer care.
About the Author
